High on-treatment platelet reactivity by more than one agonist predicts 12-month follow-up cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting

Thrombosis and Haemostasis

Volumn 104, Issue 2, 2010, Pages 279-286

  Marcucci, Rossella ^a,b   Gori, Anna Maria ^a,b,c   Paniccia, Rita ^a,b   Giusti, Betti ^a,b   Valente, Serafina ^b   Giglioli, Cristina ^b   Buonamici, Piergiovanni ^b   Antoniucci, David ^a   Abbate, Rosanna ^a   Gensini, Gian Franco ^a,b,c  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

^c IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

Acute myocardial infarction; Aspirin resistance; Atherothrombosis

Indexed keywords

ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; COLLAGEN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CORONARY STENT; DEATH; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; LIGHT TRANSMISSION AGGREGOMETRY; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

ACUTE CORONARY SYNDROME; ADENOSINE DIPHOSPHATE; ADULT; AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON, CORONARY; ARACHIDONIC ACID; CARDIOVASCULAR DISEASES; CHI-SQUARE DISTRIBUTION; COLLAGEN; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ITALY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; ODDS RATIO; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; STENTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77955475912     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-01-0007     Document Type: Article

References (30)

1. Krasopoulos G, Brister SJ, Beattie WS, et al. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. Br Med J 2008; 336: 195-198. (Pubitemid 351212675)
2. Sofi F, Marcucci R, Gori AM, et al. Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events - A meta-analysis. Int J Cardiol2008; 128: 166-171.
3. Snoep JD, Hovens MM, Eikenboom JC, et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007; 167: 1593-1599.
4. Snoep JD, Hovens MM, Eikenboom JC, et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 2007; 154: 221-231. (Pubitemid 47069129)
5. Buonamici PG, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007; 24: 2312-2317. (Pubitemid 46891710)
6. Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008; 29: 992-1000. (Pubitemid 351844676)
7. Sibbing D, Braun S, Jawansky S, et al. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thromb Haemost 2008; 99: 121-126.
8. Aleil B, Ravanat C, Cazenave JP, et al. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005; 3: 85-92. (Pubitemid 41647119)
9. Frere C, Cuisset T, Quilici J, et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost 2007; 98: 838-843. (Pubitemid 47555077)
10. Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008; 51: 1404-1411. (Pubitemid 351447314)
11. Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay. A 12-month follow-up. Circulation 2009; 119: 237-242.
12. Kuliczkowsi W, Witkowski A, Polonski L, et al. Interindividual variability in the response to oral antiplatelet drugs: a position apper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovacular Interventions of the Polish cardiac society, endorsed by the Working group on thrombosis of the European society of cardiology. Eur Heart J 2009; 30: 426-435.
13. Frelinger AL, Li Y, Linden MD, et al. Association of cyclooxigenase-1- dependent and - independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation 2009; 120: 2586-2596.
14. De Miguel Castro A, Cuellas Ramon C, Diego Nieto A, et al. Post treatment platelet reactivity predicts long term adverse events better han the response to clopidogrel in patients with non-ST-segment elevation acute coronary syndrome. Rev Esp Cardiol 2009; 62: 126-135.
15. Foussas SG, Zairis MN, Tsirimpis VG, et al. The impact of aspirin resistance on the long term cardiovascular mortality in patients with non-ST segment elevation acute coronary syndromes. Clin Cardiol 2009; 32: 142-147.
16. Geisler T, Grass D, Bigalke B, et al. The Residual platelet aggregation after deployment of intracoronary stent (PREDICT) score. J Thromb Haemost 2008; 6: 54-61.
17. Hobikoglu GF, Norgaz T, Aksu H, et al. The effect of acetylsalicylic acid resistance on prognosis of aptients who have developed acute coronary sindrome durino acetylsalicylic acid therapy. Can J Cardiol 2007; 23: 201-206.
18. Hovens MM, Snoep JD, Eikelboom JC, et al. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic rview. Am Heart J 200; 153: 175-181.
19. Pamukcu B, Oflaz H, Oncul A, et al. The role of aspirin resistance on outcome in patients with acute coronary sindrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events. J thromb Thrombolysis 2006; 22: 103-110. (Pubitemid 44473559)
20. 2007 Focused Update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. J Am Coll Cardiol 2008; 51: 172-209.
21. Paniccia R, Antonucci E, Gori AM, et al. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost 2007; 5: 1839-1847. (Pubitemid 47288940)
22. Shankar H, Garcia A, Prabhakar J, et al. P2Y12 receptor-mediated potentiation of thrombin-induced thromboxane A2 generation in platelets occurs through regulation of Erk1/2 activation. J Thromb Haemost 2006; 4: 638-647.
23. Andrè P, La Rocca T, Delaney SM, et al. Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis. Circulation 2003; 108: 2697-2703. (Pubitemid 37466813)
24. Varga-Szabo D, Pleines I, Nieswandt B. Cell adhesion mechanisms in platelets. Arterioscler Thromb Vasc Biol 2008; 28: 403-412.
25. Wiviott SD, Braunwald E, McCabe CH, et al.; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
26. Angiolillo DJ, Shoemaker SB, Desai B, et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the optimizing Antiplatelet therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 2007; 115: 708-716. (Pubitemid 46294761)
27. Jeong YH, Lee SW, Choi BR, et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity. J Am Coll Cardiol 2009; 53: 1101-1109.
28. Valgimigli M, Campo G, de Cesare N, et al. Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R). Rationale for the study and protocol design. Cardiovasc Drugs Ther 2008; 22: 313-320.
29. Becker RC, Moliterno DJ, Jennings LK, et al.; TRA-PCI investigators. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomized, double-bind, placebo-controlled phase II study. Lancet 2009; 373: 919-928.
30. Gori AM, Marcucci R, Migliorini A, et al. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol 2008; 52: 734-739.